PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease

International Journal of Cardiology

Volumn 91, Issue 1, 2003, Pages 43-51

  Azarsiz, Elif ^a   Kayikcioǧlu, Meral ^a   Payzin, Serdar ^a   Sözmen, Eser Yildirim ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Antioxidant enzymes; Coronary angiography; Coronary disease; ox LDL; PON1

Indexed keywords

ALKADIENE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CATALASE; LOW DENSITY LIPOPROTEIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PARAMETER; PATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; STIMULATION;

EID: 0041828191     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00595-8     Document Type: Article

References (31)

1. Ross R. Atherosclerosis: an inflammatory disease. New Eng J Med. 340:(2):1999;115-126.
2. Aviram M. Interaction of oxidised low density lipoprotein with macrophages in atherosclerosis and the atherogenicity of antioxidants. Eur J Clin Biochem. 34:1996;599-608.
3. Jialal I., Devaraj S. Low density lipoprotein oxidation, antioxidants and atherosclerosis. A clinical biochemistry perspective. Clin Chem. 42:(4):1996;498-506.
4. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
5. Chisolm G.M., Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Rad Biol Med. 28:(12):2000;1815-1826.
6. Kaplan M., Aviram M. Oxidized low density lipoprotein: atherogenic and proinflamatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med. 37:(8):1999;777-787.
7. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 272:(34):1997;20963-20966.
8. Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in atherogenesis: an appraisal. J Lipid Res. 40:1999;2143-2157.
9. Woodside J.V., Young I.S., Yarnell J.W.G., et al. Antioxidants but not B group vitamins increase the resistance of low density lipoprotein to oxidation: randomized, factorial design, placebo-controlled trial. Atherosclerosis. 144:1999;419-427.
10. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7:1996;69-76.
11. Laplaud R.M., Dantoine T., Chapman M.J. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med. 36:(7):1998;431-441.
12. Durrington P.N., Mackness B., Mackness M.I. Role of HDL in preventing atherogenic modification of LDL. Atherosclerosis. 146:(suppl):1999;813.
13. Shih D.M., Gu L., Hama S., et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 97:(7):1996;1630-1639.
14. Mates J.M., Perez-Gomez C., De Castro I.N. Antioxidant enzymes and human diseases. Clin Biochem. 32:(8):1999;595-603.
15. Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in atherogenesis; an appraisal. J Lipid Res. 40:1999;2143-2157.
16. Sözmen E.Y., Sözmen B., Delen Y., Onat T. Catalase/superoxide dismutase and catalase (paraoxonase ratios may implicate poor glycemic control. Arch Med Res. 32:2001;283-287.
17. Sözmen EY, Sözmen B, Girgin FK, Delen Y, Azarsiz E, Erdener D, Ersz B. Antioxidant enzymes and paraoxonase show co-activity in preserving LDL from oxidation. Clin Exp Med (in press).
18. Austen W.G., Edwards J.E., Frye R.L., et al. A reporting system on patients evaluated for coronary artery disease. Circulation. 51:(4 suppl):1975;5-40.
19. Eckerson H.W., Wyte C., La Du B.N. The human serum paraoxonase/arylsterase polymorphism. Am J Hum Genet. 35:1983;1126-1138.
20. Sözmen E.Y., Tanyalçin T., Kutay F., Onat T. Ethanol induced oxidative stress and membrane injury in rats. Eur J Clin Chem Clin Biochem. 32:1994;741-744.
21. Taus M., Ferretti G., Dousset N., et al. Susceptibility to in vitro lipid peroxidation of low density lipoproteins and erythrocyte membranes from liver cirrhotic patients. Scand J Clin Lab Invest. 54:1994;147-153.
22. Halevy D., Thiery J., Nagel D., et al. Increased oxidation of LDL in patients with coronary artery disease is independent from dietary vitamins E and C. Arterioscler Thromb Vasc Biol. 17:1997;1432-1437.
23. Regnström J., Nillson J., Tornvall P., Landau C., Hamsten A. Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet. 339:(5):1992;1183-1186.
24. Goodfellow J., Owens D., Henderson A. Cardiovascular syndromes X, endothelial dysfunction and insulin resistance. Diab Res Clin Prac. 31:(suppl):1996;S163-171.
25. Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmac. 31:(3):1998;329-336.
26. Aviram M., Rosenblat M., Scott B., et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Rad Biol Med. 26:(7/8):1999;892-904.
27. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parma S.L., LaDu B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 101:(8):1998;1581-1590.
28. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 96:1995;2882-2891.
29. Sözmen E.Y., Kerry Z., Uysal F., et al. Antioxidant enzyme activities and total nitrite/nitrate levels in the collar model: effect of nicardipine. Clin Chem Lab Med. 38:(1):2000;21-25.
30. Lankin V.Z., Vikhert A.M., Kosykh V.A., Tikhaze A.K., Galakhov L.E., Orekhov A.N. Enzymatic detoxication of superoxide anion radicals and lipoperoxides in intima and media of atherosclerotic aorta. Biomed Biochim Acta. 43:1984;797-802.
31. Galvani M., Ferrini D., Ghezzi F., Ottani F. Cardiac markers and risk stratification: an integrated approach. Clin Chim Acta. 311:2001;9-17.